Literature DB >> 6815823

Low-dose aspirin inhibits platelet and venous cyclo-oxygenase in man.

F E Preston, M Greaves, C A Jackson, C J Stoddard.   

Abstract

In a group of normal subjects we have compared rates of recovery of venous prostacyclin (PGI2) and platelet thromboxane B2 (TXB2) production after a single 300 mg dose of aspirin. Marked inhibition of both venous PGI2 synthesis and platelet TXB2 synthesis persisted for the 72 hours duration of the study. We also examined the effect of four daily doses of 40 mg aspirin on platelet and vessel wall prostaglandin biosynthesis. This produced a cumulative inhibitory effect on TXB2 production with 98.6 per cent mean inhibition at 72 hours. At this time 81-100 per cent inhibition of PGI2 was demonstrated in the four subjects studied. We conclude that the cyclo-oxygenase enzyme in human vein is sensitive to inhibition by very low doses of aspirin. No evidence was found to substantiate the view that rapid recovery of vessel wall cyclo-oxygenase activity occurs after inhibition by a single dose of aspirin.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6815823     DOI: 10.1016/0049-3848(82)90065-2

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Biochemical selectivity of oral versus intravenous aspirin in rats. Inhibition by oral aspirin of cyclooxygenase activity in platelets and presystemic but not systemic vessels.

Authors:  C Cerletti; M C Gambino; S Garattini; G de Gaetano
Journal:  J Clin Invest       Date:  1986-07       Impact factor: 14.808

Review 2.  Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

Authors:  Timothy D Warner; Sven Nylander; Carl Whatling
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 3.  Current issues in thrombosis prevention with antiplatelet drugs.

Authors:  G de Gaetano; C Cerletti; E Dejana; J Vermylen
Journal:  Drugs       Date:  1986-06       Impact factor: 9.546

4.  The effectiveness of low dose slow release aspirin as an antiplatelet agent.

Authors:  J S Budd; K Allen; A Walsh; P R Bell
Journal:  J R Soc Med       Date:  1993-05       Impact factor: 18.000

5.  Effects of aspirin on rheological properties of erythrocytes in vitro.

Authors:  Mohamed A Elblbesy; Abdel Rahman M Hereba; Mamdouh M Shawki
Journal:  Int J Biomed Sci       Date:  2012-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.